Italian study tracks Real-World use of zanubrutinib for rare blood cancer
NCT ID NCT06441214
First seen Jan 10, 2026 · Last updated May 23, 2026 · Updated 16 times
Summary
This study observes how patients with Waldenström's macroglobulinemia (a rare blood cancer) are treated with the drug zanubrutinib in Italy, both through a compassionate use program and after it was approved for sale. Researchers will track side effects and why some patients stop treatment. About 212 participants are included, and no new treatments are given—just routine care.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for WALDENSTRÖM'S MACROGLOBULINEMIA (WM) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
A.O. Ospedali Riuniti Villa Sofia-Cervello - Divisione di Ematologia
Palermo, Italy
-
A.O. SS. Antonio e Biagio e Cesare Arrigo - S.C.D.U. Ematologia
Alessandria, Italy
-
A.O.U. Città della Salute e della Scienza di Torino - Ematologia Universitaria
Torino, Italy
-
A.O.U. Città della Salute e della Scienza di Torino - S.C. Ematologia
Torino, Italy
-
A.O.U. Ospedali Riuniti - Clinica di Ematologia
Ancona, Italy
-
AOU Maggiore della Carità di Novara - SCDU Ematologia
Novara, Italy
-
AOU Pisana - U.O. Ematologia
Pisa, Italy
-
AOU Policlinico Consorziale - U.O. Ematologia con Trapianto
Bari, Italy
-
AOU Senese - U.O.C. Ematologia
Siena, Italy
-
AOU di Padova - Ematologia
Padova, Italy
-
ASST Grande Ospedale Metropolitano Niguarda - S.C. Ematologia
Milan, Italy
-
Azienda Ospedaliera Universitaria Careggi - Unità funzionale di Ematologia
Florence, Italy
-
Azienda Ospedaliera Universitaria Policlinico - S. Marco - UOC di Ematologia
Catania, Italy
-
Azienda Ospedaliero-Universitaria di Ferrara - Arcispedale Sant'Anna - Ematologia e fisiopatologia della coagulazione
Ferrara, Italy
-
Azienda Sanitaria Universitaria Friuli Centrale (ASU FC) - SOC Clinica Ematologica
Udine, Italy
-
Azienda Unità Sanitaria Locale-IRCCS - Arcispedale Santa Maria Nuova - Ematologia
Reggio Emilia, Italy
-
IEO Istituto Europeo di Oncologia - Divisione Ematoncologia
Milan, Italy
-
Nuovo Ospedale degli Infermi - SSD Ematologia
Biella, Italy
-
Ospedale "G. Mazzini" - UOS Ematologia
Teramo, Italy
-
Ospedale C. e G. Mazzoni - U.O.C. di Ematologia
Ascoli Piceno, Italy
-
Ospedale Centrale di Bolzano - Divisione di Ematologia e T.M.O.
Bolzano, Italy
-
Ospedale Maggiore Policlinico - Fondazione IRCCS Ca Granda - Ematologia
Milan, Italy
-
Ospedale Policlinico San Martino S.S.R.L. - IRCCS per l'Oncologia - Ematologia e terapie cellulari
Genova, Italy
-
Ospedale delle Croci - Ematologia
Ravenna, Italy
-
P.O. Spirito Santo di Pescara - UOC Ematologia Dipartimento Oncologico Ematologico - ASL Pescara
Pescara, Italy
-
Policlinico S. Orsola-Malpighi - Istituto di Ematologia "Seragnoli"
Bologna, Italy
-
RCCS Policlinico S. Matteo di Pavia - Div. di Ematologia
Pavia, Italy
-
Università Cattolica Sacro Cuore - Ematologia
Roma, Italy
Conditions
Explore the condition pages connected to this study.